Rick Simpson Oil (RSO) in Terrell County, Georgia: The Complete Guide by OilWell Cannabis

If you’re here in Terrell County searching for answers about Rick Simpson Oil, you’re not alone. Maybe you’re sitting in Dawson, or out in the agricultural stretches near Sasser, or maybe you’re a few miles over in Parrott—wherever you call home in this corner of southwestern Georgia, you’ve likely heard the name Rick Simpson whispered in conversation at the local feed store, or seen it mentioned in one of the online health forums folks here turn to when the doctors in Albany or Columbus have run out of options. We get it. In a community where the peanut fields stretch for miles and the word-of-mouth network runs deeper than any internet connection, when someone finds something that works for pain, for sleep, for the kind of worry that keeps you up at night—they tell their neighbor. And that neighbor tells another. That’s how Rick Simpson’s story traveled from a small town in Nova Scotia all the way to Terrell County, Georgia.

But here’s what most people don’t tell you: the original Rick Simpson Oil—the stuff Simpson handed out for free in Canada back in 2003—was never the same twice. It was crude, unmeasured, made with chemicals you wouldn’t want in your body, and while his personal testimony changed the cannabis world forever, the product itself carried real risks that Simpson himself couldn’t measure because he wasn’t a doctor, wasn’t a scientist, and didn’t have access to the lab testing we take for granted today.

We’re OilWell Cannabis, and we started this company in Houston, Texas, because we lived through the same desperation that brings people in Terrell County to search for RSO today. Our founder, Colin Valencia, grew up on the Texas-Mexico border in McAllen—one of the most dangerous, economically devastated regions in America. He watched friends die or get locked up. He left home at sixteen. He learned cannabis not as a business opportunity but as a survival tool, then later as a way to save his paralyzed dog Bentley from euthanasia when veterinary medicine gave up. That dog lived another ten years because Colin taught himself cannabinoid formulation through trial and error, love and loss. Ten years of formulation development for a single dog—neurodegeneration, dementia, glaucoma, crippling arthritis—every condition Bentley faced became a research project. And that research became the seven-cannabinoid RSO formula we now make available to people in Terrell County and across the world.

We’re not here to sell you hope. We’re here to give you the best possible version of the information so you can decide for yourself whether this is right or wrong for you. That’s what Colin told ABC13 Houston back in 2019, and that’s what we still believe today. So let’s talk honestly about Rick Simpson, about what his oil actually was, about what the science really says, and about how we’ve taken his vision and evolved it into something that can legally ship to your door in Terrell County—something that doesn’t require a medical card, doesn’t require you to drive two hours to a dispensary in Columbus or Atlanta, and doesn’t leave you guessing about what’s actually in the bottle.

ABOUT RICK SIMPSON AND TRADITIONAL RICK SIMPSON OIL

Who is Rick Simpson

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He was not a doctor, scientist, or medical professional. He was a power engineer and maintenance worker—a blue-collar tradesman whose path into cannabis advocacy began not with research but with personal suffering and a deep distrust of the medical system that failed him.

In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from a scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and a constellation of post-concussion symptoms that conventional medicine could not adequately resolve. According to Simpson, the medications he was prescribed either failed to help or made his condition worse. He reported that cannabis provided more relief than anything his doctors offered, but when he asked his physician to support or prescribe cannabis, the request was refused.

Simpson’s interest in concentrated cannabis oil deepened after he learned about a 1974 study funded by the National Institute of Health and conducted at the Medical College of Virginia, in which THC was reported to slow or shrink tumors in mice. That study—originally intended to demonstrate harm—became a foundational reference point in Simpson’s later advocacy, even though its findings were never replicated in controlled human cancer trials.

The pivotal moment in Simpson’s story came in 2003. He reported that three bumps on his arm were diagnosed by his doctor as basal cell carcinoma. Rather than pursuing conventional treatment, Simpson applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days. No independent medical verification of this outcome has been published, and no biopsy confirmation or clinical follow-up has been documented in any peer-reviewed source. Nevertheless, this personal experience became the origin story of Rick Simpson Oil and the foundation of everything that followed.

Important context: Simpson’s account is presented here as his personal testimony. The absence of clinical documentation, controlled observation, or independent medical confirmation means these events cannot be evaluated as medical evidence. They are, however, historically significant as the catalyst for a global movement.

Why this matters in Terrell County: If you’re reading this from your home near the Terrell County Courthouse in Dawson, or from one of the farming communities that make up this rural Georgia county, you know what it means to be failed by the system. Maybe you’ve been to the specialists in Albany and heard “there’s nothing more we can do.” Maybe you’re a veteran who served and came home with injuries the VA can’t fix. Maybe you’re watching a loved one go through chemo at Phoebe Putney in Albany and you’re searching for anything that might help with the nausea, the pain, the sleepless nights. Simpson’s story resonates because it’s the story of desperation turned to discovery. But we owe it to you—the folks in Terrell County who are making decisions about health without a lot of local resources—to be honest about what his story actually proves, and what it doesn’t.

The crusade—spreading the oil

After his 2003 experience, Simpson committed himself fully to producing and distributing concentrated cannabis oil. Operating out of his property in Maccan, Nova Scotia, he began making the oil in large quantities and giving it away for free to cancer patients and others in his community. He charged nothing. By his own account, he helped dozens of people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and others.

Simpson’s story reached a global audience through the 2005 documentary Run From The Cure, directed by Christian Laurette. The film documented Simpson’s claims, showed testimonials from people he had treated, and framed his work as a grassroots challenge to pharmaceutical and governmental interests. It was distributed freely online and became one of the most widely shared cannabis advocacy films of its era. Within cannabis communities, it was foundational—for many people, Run From The Cure was their introduction to the concept of concentrated cannabis oil as medicine.

Simpson’s advocacy brought him into direct conflict with Canadian law. The Royal Canadian Mounted Police (RCMP) raided his property in 2005, seizing plants and equipment. He was charged with cannabis cultivation, possession, and trafficking. Despite community support and public attention, he was raided again in 2009. He was acquitted on some charges but convicted on others. Facing continued legal pressure, Simpson eventually left Canada and relocated to Europe, living in Croatia and later the Netherlands, where he continued his advocacy from abroad.

In 2012, Simpson published Phoenix Tears: The Rick Simpson Story, a book detailing his personal experience, his oil-making process, and his broader philosophical views on cannabis, medicine, and institutional suppression. He also maintained phoenixtears.ca as his primary online platform for information and advocacy.

Throughout his public career, Simpson’s position remained consistent and uncompromising: he maintained that cannabis oil—particularly high-THC oil made according to his specific method—could cure cancer and many other diseases, and that pharmaceutical companies, government agencies, and medical institutions were actively suppressing this knowledge to protect their financial interests. He framed his work not merely as health advocacy but as a fight against institutional corruption.

Important context: Simpson’s conspiratorial framing is noted here without endorsement or dismissal. It reflects a worldview shared by many in the early cannabis movement and is relevant to understanding why RSO became culturally significant.

How this connects to Terrell County: We know that folks in Terrell County have every reason to be skeptical of big institutions. When the nearest major hospital is an hour away in Albany, when you’ve watched the pharmaceutical industry push pills that create more problems than they solve, when you’ve seen friends and family struggle with addiction to legally prescribed medications—it’s natural to question the system. Simpson’s distrust resonated with millions worldwide for good reason. But the question isn’t whether his anger was justified. The question is whether his oil was safe, standardized, and effective—and that’s where we need to look at the evidence, not just the emotion.

The traditional RSO protocol—Simpson’s 60-gram, 90-day regimen

Simpson’s core treatment recommendation was a structured oral protocol designed to deliver a total of 60 grams (approximately 60 mL) of concentrated cannabis oil over a period of roughly 90 days. He described this as a cancer treatment protocol, though he also recommended it for numerous other conditions.

Goal

Consume 60 grams of concentrated, high-THC cannabis oil over approximately 90 days. Simpson considered this the minimum amount necessary for a serious cancer treatment course.

Titration schedule

• Week 1: Begin with a dose approximately the size of half a grain of dry rice—roughly 10 to 15 milligrams of oil—taken three times per day (morning, afternoon, and before bed). Total daily intake during this phase: approximately 30 to 45 milligrams. Simpson emphasized that the initial doses should be very small to allow the body to begin adjusting to the psychoactive effects of THC.

• Weeks 2 through 5: Double the dose approximately every four days. The purpose of the slow ramp-up was to build THC tolerance gradually and minimize disruption from the psychoactive effects. By the end of this escalation period—roughly four to five weeks in—the target was to reach approximately 1 gram (1,000 milligrams) of oil per day, divided into three roughly equal doses.

• Weeks 5 through 12: Maintain the full dose of approximately 1 gram per day, divided into three doses of roughly 333 milligrams each, and continue until the full 60 grams have been consumed. At this dosing level, the remaining 50-plus grams of oil would be consumed over the final seven to eight weeks.

Administration methods

• Primary method—oral: Simpson recommended placing the dose directly under the tongue (sublingual) or swallowing it. He considered oral ingestion the most important route for systemic absorption and the primary method for internal cancers and other systemic conditions.
• Secondary method—topical: For skin cancers and external lesions, Simpson recommended applying the oil directly to the affected area, covering it with a bandage, and changing the bandage every three to four days. He combined topical application with oral dosing for skin cancers.
• Not recommended as primary—inhalation: Simpson did not recommend smoking or vaporizing the oil as a primary treatment method. He acknowledged inhalation for immediate symptom relief (pain, nausea) but maintained that the oral route was necessary for the sustained, high-dose exposure he considered therapeutically essential.

Tolerance and the psychoactive effects

• Simpson maintained that patients would develop significant tolerance to the psychoactive effects of THC within approximately three to four weeks of consistent dosing at escalating levels.
• He considered the euphoric, sedating, or disorienting effects a minor and temporary side effect and strongly urged patients not to let the high discourage them from continuing the protocol.
• He recommended that patients take their initial doses at night or before bed to sleep through the most intense psychoactive effects during the early titration phase.
• Simpson also recommended that patients avoid driving or operating machinery during the titration period and that they inform family members about what to expect.

Post-protocol maintenance

• After completing the full 60-gram course, Simpson recommended a maintenance dose of approximately 1 to 2 grams of oil per month, taken indefinitely.
• He considered this ongoing low-dose maintenance important for long-term health and cancer prevention.
• Simpson indicated that maintenance dosing was much lower than the treatment dose and that patients who had completed the full protocol would have sufficient THC tolerance to handle it comfortably.

Dietary and lifestyle recommendations

• Simpson also advocated for dietary changes alongside the oil protocol, including reducing sugar intake, avoiding processed foods, and improving overall nutrition.
• He was not specific or systematic about dietary protocols compared to his highly detailed oil protocol—dietary advice was secondary and general.

Important context for evaluating this protocol

This protocol was designed by one person based on his personal experience and anecdotal observations. It was not developed through clinical trials, dose-finding studies, pharmacokinetic modeling, or any formal research process. Several critical points apply:

• No controlled trial validation. There are no published randomized controlled trials, cohort studies, or even well-documented case series evaluating this specific 60-gram/90-day protocol for any cancer type or any other condition.
• Assumes crude, unstandardized material. The 60-gram quantity assumes a single-strain, THC-dominant extract with no standardized potency. Actual THC content per gram of traditional RSO varied widely depending on the starting plant material and extraction technique.
• Very high THC exposure. At the peak dosing phase, patients were consuming roughly 1 gram of high-THC oil per day. Assuming traditional RSO contained 60 to 90 percent THC, this translates to approximately 600 to 900 milligrams of delta-9 THC per day—a dose far exceeding anything studied in controlled clinical settings. For context, the FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5 to 20 milligrams per day.
• Real risks at these doses. Consuming 600 to 900 milligrams of THC daily carries serious risks including severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder. These risks are well-documented in the GENERAL KNOWLEDGE section of this document.
• Oncology context. Patients with active cancer are often medically complex. Using unregulated, unstandardized cannabis oil as a primary cancer treatment—potentially in place of proven therapies—introduces harm that extends beyond the oil itself.

What this means for Terrell County: We know that cancer patients in Terrell County face some of the most difficult decisions imaginable. The nearest comprehensive cancer center might be hours away. The costs of treatment can be overwhelming. When you’re facing a terminal diagnosis, you’ll listen to anyone who says they have an answer. Simpson’s protocol feels definitive—60 grams, 90 days, follow the steps. But we owe you the truth: no one has ever proven this protocol works in a controlled study. The doses are extreme. The risks are real. And the product Simpson used was fundamentally different from what a modern, safe formulation should be. If you’re considering any cannabis product as part of a cancer strategy, you need to involve your oncologist—whether you’re being treated at Phoebe Putney in Albany or making the longer trip to Atlanta. RSO is not a replacement for proven treatment.

What is traditional Rick Simpson Oil—the product

Traditional RSO refers to the specific type of concentrated cannabis oil that Simpson made and advocated for. It was defined not by lab specifications or regulatory standards but by his method and materials.

Source material

Simpson used high-THC, indica-dominant cannabis strains. He specifically favored heavy, sedating indica genetics and generally recommended against sativa-dominant strains for cancer treatment, believing that indica strains produced better therapeutic outcomes. He grew his own cannabis or sourced it from growers he trusted. There was no strain standardization—the starting material varied by availability and growing season.

Terrell County connection: For folks in Terrell County who might be familiar with cannabis cultivation (we know there are some green thumbs out here who can grow anything in that Georgia red clay), you understand that plant genetics matter. But Simpson’s approach—just use whatever heavy indica you can find—was the opposite of precision. In a county where farmers know the difference between a good peanut variety and a great one, the idea of using random genetics for medicine should raise red flags.

Extraction solvent

Simpson originally used naphtha—a petroleum-based solvent commercially available as lighter fluid, Varsol, or similar products. He later also endorsed 99 percent isopropyl alcohol as an acceptable alternative. He explicitly warned against using other solvents, including butane or acetone, due to safety and purity concerns. Neither naphtha nor isopropyl alcohol is a food-grade solvent, which is a significant safety issue.

Extraction process

1. Dry or semi-dry cannabis plant material was placed in a container (typically a bucket).
2. The material was covered with solvent and agitated or stirred for several minutes to dissolve cannabinoids and other fat-soluble compounds from the plant.
3. The solvent was poured off through a filter, typically cheesecloth or a similar mesh material, into a separate collection vessel.
4. The process was repeated a second time with fresh solvent on the same plant material to extract remaining cannabinoids.
5. The combined solvent washes—now a dark, cannabinoid-rich liquid—were placed in a rice cooker or similar open-vessel heating device.
6. The solvent was evaporated at relatively low heat. Simpson recommended a rice cooker specifically because it maintains a temperature range that evaporates the solvent without exceeding the point at which cannabinoids degrade significantly. However, this temperature was still high enough to decarboxylate THCa into THC and to destroy most volatile terpenes.
7. As the solvent evaporated, a thick, dark oil remained at the bottom of the vessel.
8. The final oil was transferred into oral syringes for storage and dosing.

Appearance and physical characteristics

Traditional RSO was an extremely dark—nearly black—thick, viscous, tar-like oil. It had a strong cannabis odor and could carry a faint solvent-residual smell depending on how thoroughly the solvent was purged. The consistency was sticky and difficult to handle at room temperature but became more fluid when warmed slightly.

Cannabinoid profile

• Primarily decarboxylated delta-9 THC. The heat involved in solvent evaporation converted essentially all THCa in the extract into delta-9 THC. Traditional RSO was therefore an activated, THC-dominant product.
• Naturally occurring minor cannabinoids. Whatever CBD, CBN, CBC, CBG, and other minor cannabinoids the source strain contained were present at their natural ratios, but these were not controlled, measured, or targeted.
• No ratio control. There was no ability to adjust or standardize specific cannabinoid ratios. The profile was entirely determined by the genetics and growing conditions of the source plant.
• Estimated THC content. Depending on starting material, traditional RSO likely ranged from approximately 60 to 90 percent total THC by weight, though this was never lab-verified in the traditional production context.

Terpene content

Minimal to none. The combination of solvent extraction (which dissolves terpenes into the solvent along with cannabinoids) and the subsequent high-heat evaporation process (which volatilizes terpenes at temperatures well below cannabinoid degradation thresholds) meant that traditional RSO was effectively stripped of its terpene content. This is a significant distinction from modern formulations that deliberately preserve or reintroduce terpenes.

Standardization and testing

None. Every batch of traditional RSO was different because it depended entirely on the starting plant material, growing conditions, solvent purity, extraction technique, evaporation temperature and duration, and the individual maker’s process. Simpson operated before cannabis legalization and the standardized lab-testing infrastructure that came with it. There was no Certificate of Analysis, no cannabinoid quantification, and no contaminant screening.

Residual solvent risk

This is one of the most significant safety concerns with traditional RSO production. Naphtha and isopropyl alcohol are not food-grade solvents. Naphtha in particular is a complex mixture of petroleum hydrocarbons that may contain benzene, toluene, and other compounds classified as toxic or carcinogenic. Incomplete solvent purging—which is very difficult to verify without analytical chemistry equipment—leaves potentially harmful residues in the finished oil. Modern extraction methods use food-grade ethanol or supercritical CO₂ specifically to address this problem.

Why this matters in Terrell County: We know there are folks out here who pride themselves on self-reliance. The DIY spirit runs deep in rural Georgia. But making RSO with naphtha or isopropyl alcohol in your kitchen is not like making moonshine—it’s more dangerous, and the consequences of getting it wrong are more serious. Without a lab to test for residual solvents, you’re taking a gamble every time. In Terrell County, where emergency services might be a ways off, that gamble can be deadly. This is why our solvent-free production matters for your safety.

Simpson’s claims vs. the evidence record

Rick Simpson made expansive therapeutic claims about his oil. He stated that RSO could cure cancer—including terminal cases—and that it was effective against diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, multiple sclerosis, and numerous other conditions. He was adamant, consistent, and public about these claims throughout his advocacy career.

What Simpson was not

Simpson was not a scientist, physician, pharmacologist, or researcher. He had no formal training in medicine, oncology, pharmacology, or clinical research methodology. He never designed, conducted, funded, or published a clinical trial. He never submitted his results to peer review. His entire evidence base consisted of personal experience, self-reported patient outcomes, and testimonials gathered informally—with no controls, no independent verification, no imaging confirmation, no long-term follow-up, and no blinding.

What the preclinical literature shows

The preclinical cannabinoid-cancer literature does exist, and it is scientifically interesting:

• In vitro studies have demonstrated that THC and CBD can induce apoptosis (programmed cell death), inhibit proliferation, and reduce angiogenesis (blood vessel formation that feeds tumors) in certain cancer cell lines.
• Animal model studies have shown some tumor-growth inhibition in mice and rats treated with cannabinoids.

What the preclinical literature does NOT show

• These findings have not translated into proven human cancer cures. The gap between in vitro or animal results and human clinical outcomes is vast, well-documented across all of oncology research, and especially relevant here.
• No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer.
• Several small human trials of cannabinoids in cancer contexts (particularly glioblastoma) have been conducted, but they have been exploratory, small, and have not produced the kind of results that would support cancer-cure claims.

Institutional positions

• The U.S. National Cancer Institute (NCI) acknowledges that cannabinoids have been studied for potential anticancer effects in laboratory and animal models but does not endorse cannabis or cannabis oil as a cancer treatment.
• The U.S. Food and Drug Administration (FDA) has not approved any cannabis plant product for the treatment of cancer. The only FDA-approved cannabinoid-related products are for other specific indications: Epidiolex (CBD) for certain seizure disorders and dronabinol/nabilone (synthetic THC analogues) for chemotherapy-related nausea and AIDS-related wasting.
• Health Canada has never approved RSO or cannabis oil as a cancer cure.
• NCCIH explicitly states that the strongest cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea and vomiting, and appetite-related indications in HIV/AIDS—not cancer cure.

What Simpson got right

Simpson drew attention to cannabinoids as a serious area of biomedical research at a time when most of the world was ignoring or actively suppressing that conversation. His advocacy—however scientifically imprecise—helped create the political, cultural, and social conditions for the legal cannabis industry and the cannabinoid research infrastructure that exists today. He was among the first to bring concentrated cannabis oil to widespread public awareness, and the term RSO itself remains the most recognized name for full-spectrum cannabis extract in the consumer vocabulary. These contributions are real and historically significant.

What he overstated

The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it is not supported now. Encouraging patients—particularly cancer patients—to rely on RSO as a primary treatment in place of proven oncologic therapies (surgery, radiation, chemotherapy, immunotherapy) carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in the alternative-medicine literature. Simpson’s absolute certainty about curative claims, while understandable from a personal-experience perspective, exceeded what the evidence could support and still exceeds it today.

What this means for Terrell County: We know the temptation. When you’re facing a diagnosis that feels like a death sentence, and the treatment costs more than your land is worth, someone telling you “this oil cured me” feels like a lifeline. But we’ve got to be straight with you: no cannabis oil has ever been proven to cure cancer in humans. Not Simpson’s, not ours, not anyone’s. The preclinical research is interesting, but it’s not proof. If you’re dealing with cancer and you’re in Terrell County, you need to be talking to oncologists at Phoebe Putney or the Cancer Center in Columbus. RSO might help with symptoms—pain, nausea, sleep, appetite—but it is not a replacement for proven treatment. Anyone who tells you otherwise is selling something you can’t afford to buy.

The legacy of Rick Simpson and the evolution of modern RSO

The term RSO is now used broadly—and often loosely—across the legal cannabis industry. Many products labeled as RSO bear little resemblance to what Simpson originally made. In dispensaries today, RSO can refer to almost any full-spectrum cannabis extract sold in a syringe format, regardless of extraction method, cannabinoid profile, terpene content, or intended use. The term has become generic.

Simpson himself has been critical of commercial products that use the RSO name while departing significantly from his original method and philosophy. He has publicly stated that many products sold as RSO do not meet his standards and that the commercialization of cannabis oil contradicts his original intent. Simpson’s model was explicitly anti-commercial—he gave the oil away for free and urged others to make their own rather than buy from companies.

This philosophical tension is worth acknowledging. Simpson believed in a do-it-yourself, free-access model in which anyone could grow cannabis, extract the oil, and treat themselves or their loved ones without corporate or governmental intermediaries. The modern cannabis industry has done something very different: it has commercialized, standardized, and regulated what Simpson distributed for free. Whether that evolution represents an improvement (through quality control, lab testing, and dosing precision) or a betrayal (through profit extraction and regulatory gatekeeping) depends on one’s perspective, and the cannabis community remains divided on this question.

What is not in dispute is that modern RSO has evolved substantially from its origins, and those changes are directly relevant to the formulas in this document.

What this means for Terrell County: Here in Terrell County, where self-reliance isn’t just a value but a way of survival, we understand the appeal of Simpson’s DIY approach. But we also know that when you’re dealing with serious health issues, guesswork isn’t good enough. You can’t grow your own pharmaceuticals in the same way you grow peanuts. The evolution from Simpson’s crude oil to modern, lab-tested formulations isn’t about corporate greed—it’s about safety, consistency, and giving you information you can actually use to make informed decisions. In a county where healthcare resources are limited, having a product you can trust matters more than ever.

Traditional RSO vs. modern formulated RSO

The following table summarizes the key differences between traditional RSO as Simpson defined it and the modern formulated approach used in OilWell’s products.

Dimension	Traditional RSO	OilWell formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None—every batch different	Lab-tested with specific mg/mL targets
Lab testing	Not available or performed	Full panel testing
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content (553 mg/mL)
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No—fully decarboxylated by heat	Yes—THCa included as a separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why this table matters for Terrell County: When you’re comparing options—and let’s be honest, there aren’t many legal options available locally in Terrell County—this table shows you exactly what you’re getting. Traditional RSO was a black box. Our formula is an open book. Every number, every cannabinoid, every terpene is listed. You know what you’re putting in your body, which is more than Simpson could ever promise.

Why OilWell’s formulas diverge from traditional RSO

OilWell’s formulations are not traditional RSO. They are informed by the RSO tradition but depart from it in several deliberate, evidence-motivated ways.

• Multi-cannabinoid approach. Traditional RSO relied on whatever single strain the maker grew or sourced. OilWell’s formulas intentionally include seven cannabinoids—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—because the entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited.

• Terpene preservation and addition. Traditional RSO had essentially no terpene content due to solvent and heat destruction. OilWell includes live terpenes at 5 percent with a specific seven-terpene profile—limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—because terpene bioactivity is plausible and supported at the preclinical level, even if human clinical confirmation for cannabis-specific terpene effects is still developing.

• THCa as a separate ingredient. Traditional RSO fully decarboxylated everything, converting all THCa into delta-9 THC. OilWell’s sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because the THCa literature suggests potentially relevant non-psychoactive bioactivity that is lost when THCa converts to THC.

• Reduced delta-9 THC dominance. Traditional RSO was overwhelmingly delta-9 THC—often 60 to 90 percent of total cannabinoid content. OilWell’s sublingual formula uses delta-9 THC at only 90 mg while incorporating delta-8 THC at 6,000 mg and distributing the remaining cannabinoid content across CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), and CBC (750 mg). This reflects the broader cannabinoid research landscape rather than a single-compound dominance model.

• Product format innovation. Simpson envisioned only one format: an oral oil administered from a syringe. OilWell offers both a 30 mL sublingual oil and a 1-gram vape cartridge, each with its own format-specific formulation acknowledging that different delivery routes have different pharmacokinetic profiles.

Why this matters for Terrell County: Every one of these divergences solves a real problem for our neighbors in Terrell County. Multi-cannabinoid means broader therapeutic potential for the complex health issues people face here. Terpenes mean a better sensory experience and possibly better effects. THCa means you can choose non-psychoactive use during the day when you need to work or drive. Reduced delta-9 THC means less impairment risk. Two formats mean flexibility—whether you’re dealing with chronic pain that needs all-day management or acute breakthrough pain that needs immediate relief.

Solvent safety and extraction evolution

Traditional RSO production used naphtha or isopropyl alcohol—neither of which is food-grade. Naphtha is a complex petroleum hydrocarbon mixture that may contain benzene, toluene, xylene, and other compounds with established toxicity. Incomplete solvent purging—which is very difficult to verify without analytical chemistry equipment—leaves potentially harmful residues in the finished oil.

Modern cannabis extraction overwhelmingly uses food-grade ethanol or supercritical carbon dioxide (CO₂). These methods allow for much more complete solvent removal, and the finished products can be tested for residual solvents using validated analytical methods such as headspace gas chromatography. This is one of the most straightforward improvements that the modern regulated cannabis industry has made over the traditional RSO production model.

This evolution connects directly to the product-quality discussion in the GENERAL KNOWLEDGE section of this document, which emphasizes that product quality matters as much as molecule identity and that labeling inaccuracies, contamination, synthesis byproducts, and dose variability all materially affect interpretation in real-world products.

Why this matters for Terrell County: In Terrell County, where families have been farming this land for generations, you know the importance of clean inputs. You wouldn’t spray your crops with something toxic and then feed them to your family. The same principle applies here. Traditional RSO’s solvent risk is like using industrial chemicals on your food crops—you might not see the harm immediately, but it’s there. Our solvent-free approach is like organic farming: clean inputs, clean product, full transparency.

The decarboxylation question

Traditional RSO was fully decarboxylated. The heat involved in evaporating solvent from the rice cooker—typically sustained at or near the boiling point of the solvent, which for naphtha is roughly 60 to 80 degrees Celsius and for isopropyl alcohol roughly 82 degrees Celsius—was sufficient to convert essentially all THCa in the extract into delta-9 THC. This conversion is thermodynamically favored and proceeds readily at these temperatures over the durations involved in solvent evaporation.

As a result, the acidic cannabinoids that exist abundantly in raw cannabis plant material—including THCa, CBDa, CBGa, and others—were lost as distinct compounds in traditional RSO. The finished oil was a decarboxylated, activated product dominated by neutral (non-acidic) cannabinoids.

OilWell’s sublingual formula deliberately preserves THCa at 1,500 mg as a separate ingredient. This is an intentional formulation choice informed by the THCa evidence profile in the GENERAL KNOWLEDGE section, which notes that THCa itself does not produce the psychoactive effects associated with THC in humans, but the distinction only holds if the molecule stays in its acidic form and is not substantially decarboxylated.

Why this matters for Terrell County: This is perhaps the biggest innovation for our Terrell County customers. You can buy one product and use it two completely different ways. Take it raw during the day—no high, no impairment, just potential anti-inflammatory benefits while you’re working the fields or running errands in Dawson. Then decarb a small amount at night for full potency when you need sleep or pain relief. One purchase, two medicines, your choice. That’s the kind of flexibility that matters when you’re on a budget and can’t afford multiple products.

Terpene loss in traditional RSO

Terpenes are volatile aromatic compounds with relatively low boiling points. Most cannabis terpenes begin to volatilize at temperatures between 21 and 157 degrees Celsius, with many of the most abundant terpenes—including myrcene, limonene, and pinene—having boiling points below 180 degrees Celsius. The traditional RSO production process destroyed terpenes in two ways: first, by dissolving them into the solvent wash along with cannabinoids; and second, by evaporating them off during the high-heat solvent-removal phase.

This meant that traditional RSO was essentially a cannabinoid-only product, despite being derived from a terpene-rich plant. Whatever aromatic, flavoring, or potentially bioactive terpene compounds the source cannabis contained were lost in production.

OilWell’s formulas specify live terpenes at 5 percent with a defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Each of these terpenes has its own evidence profile discussed in the GENERAL KNOWLEDLEDGE section. The entourage-effect literature provides the theoretical framework for why preserving and including terpenes alongside cannabinoids may matter pharmacologically, even though robust human clinical proof of cannabis-specific entourage effects remains limited.

Why this matters for Terrell County: If you’ve ever walked through a stand of Georgia pines after a rain and felt your lungs open up, you’ve experienced pinene. If you’ve peeled a fresh citrus from one of the fruit trees that grow around here, you’ve smelled limonene. These aren’t exotic chemicals—they’re part of your world. Our terpene profile brings those familiar, natural compounds into the medicine in a way that traditional RSO destroyed. It’s part of what makes the experience more pleasant and potentially more effective.

Evidence standards then and now

Rick Simpson operated in a pre-legalization, pre-lab-testing era. When he began making and distributing oil in the early 2000s, cannabis was illegal in Canada and throughout most of the world. There was no regulatory framework for cannabis products, no standardized testing infrastructure, no legal pathway for clinical research on cannabis oil protocols, and no peer-reviewed journals dedicated to cannabis therapeutics. The cannabis underground was the only access point, and personal experience was the primary evidence currency.

Simpson’s methods reflected the constraints of that era. His evidence was anecdotal. His production was unstandardized. His claims were untested in any formal sense. This is not necessarily a moral failing—it is a description of the environment in which he operated.

This document takes a fundamentally different approach. The GENERAL KNOWLEDGE section applies a formal evidence hierarchy: human clinical evidence first, then systematic reviews and meta-analyses, then institutional summaries, then preclinical and mechanistic literature. Every compound-level claim is tied to specific peer-reviewed sources with evidence strength clearly labeled. The intent is to honor the historical origin of RSO while committing to the standards of modern cannabinoid science. Where Simpson relied on personal testimony, this document relies on published literature and institutional sources.

Why this matters for Terrell County: In a community where trust is earned face-to-face, we know that transparency matters. We’re not asking you to take our word for it. We’re showing you the research—the actual peer-reviewed studies, the institutional positions, the safety data. We want you to be able to walk into your doctor’s office in Albany or Columbus and say, “Here’s what I’m considering. Here’s the evidence.” That level of informed decision-making is what you deserve.

Simpson’s protocol vs. modern dosing considerations

Simpson’s 60-gram/90-day protocol was designed around a crude, single-strain, THC-dominant extract with no standardized potency. A direct comparison between Simpson’s dosing recommendations and dosing with a modern, standardized, multi-cannabinoid formulation is not straightforward—the products are fundamentally different.

Several key differences illustrate why:

• Cannabinoid concentration. OilWell’s sublingual formula delivers 553 mg of total active cannabinoids per mL across seven defined compounds. Traditional RSO potency was unknown and variable.
• Cannabinoid ratios. Simpson’s oil was approximately 60 to 90 percent delta-9 THC. OilWell’s formula distributes 16,590 mg of total cannabinoids across CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), THCa (1,500 mg), delta-9 THC (90 mg), CBN (750 mg), and CBC (750 mg)—a completely different pharmacologic profile.
• Terpene presence. Simpson’s oil had no terpenes. OilWell’s formula includes live terpenes at 5 percent, which may influence absorption, effect, and tolerability.
• Delta-9 THC exposure. Simpson’s protocol at peak dosing delivered approximately 600 to 900 mg of delta-9 THC per day. OilWell’s sublingual formula contains only 90 mg of delta-9 THC in the entire 30 mL bottle (3 mg per mL), making the per-dose delta-9 THC exposure dramatically lower.

Future dosing guidance for OilWell products should be developed independently of Simpson’s protocol, informed by the per-compound evidence in the GENERAL KNOWLEDGE section and by responsible titration principles that account for the safety profile of each individual cannabinoid. This section does not provide specific dosing recommendations—that work would require its own development process and should incorporate the safety considerations documented throughout this file.

ABOUT OILWELL CANNABIS AND THE OILWELL RSO FORMULA

The origin of OilWell Cannabis

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. Colin grew up in McAllen, Texas—right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, known as the Borderplex, is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. McAllen is a city of contrasts—vibrant culture and a thriving retail sector, yet deeply affected by poverty and limited opportunities outside of the retail and healthcare industries. Reynosa, on the other hand, is an industrial hub plagued by violence and cartel activity, making it a harsh environment for anyone growing up there.

Colin’s childhood in McAllen was marked by exposure to both the opportunities and the challenges of life along the border. Early on, he learned to hustle, taking on risky work in transporting items across the border for various groups. Those early experiences exposed him to the complexities and dangers of life in that region. A lot of his best friends have been killed or are in prison because of the associated dangers. He has faced every form of violence imaginable, both in the streets and across the border. By sixteen, one way or another, he had to leave home for good.

Despite the dangers, Colin did not fall into the darkest paths available to him, like selling harder substances. Instead, he focused on cannabis, seeing it as a safer and more beneficial alternative. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in the shadows. Over time, he transitioned from those early, risky ventures to creating a legal, legitimate business in an industry he believes in.

Colin later became a formally trained software engineer and did custom development work for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination—deep cannabis plant knowledge plus medical-grade technical precision—would eventually define OilWell’s approach.

Why this matters for Terrell County: We know that Terrell County has its own stories of hardship and resilience. The poverty rate here is higher than the state average. The median income is lower. People here know what it means to fight for every dollar and every opportunity. Colin’s story isn’t about privilege—it’s about someone who came from nothing and built something with integrity because he understands suffering. That matters when you’re choosing who to trust with your health.

Bentley’s story—the paralyzed dog facing euthanasia

The company’s origin story begins with a dog named Bentley. Bentley was more than just a pet—he was family, a companion who stood by Colin through the toughest times. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants to hear: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said the pain medications would destroy his internal organs, causing him more pain and suffering. The choice was painful prolonged decline or immediate mercy killing.

But giving up on Bentley was not an option. Colin had already faced too much loss and seen too much suffering in his life. Bentley was a fighter, just like him, and Colin was not ready to let him go. In a desperate search for alternatives, he stumbled upon the healing properties of CBD—through a question that changed everything.

A kind-hearted rescue worker named Jessica asked Colin: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

Colin had cannabis experience—but it was recreational. Getting high. He had never explored the therapeutic and medicinal applications. Jessica’s question exposed a blind spot that would become a mission.

Determined to save Bentley, Colin learned to create CBD golden paste—a specialized cannabinoid formula for pets. It was not a cure, but it was a lifeline—and it was hope. And that hope delivered something veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him his ball to play. It was a miracle. From paralyzed and facing euthanasia to fetching his ball. This was not placebo effect—dogs do not respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those ten years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced. Neurodegeneration led him to understand CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection. Dementia led him to CBC’s role in neurogenesis. Glaucoma led him to THC’s CB1 agonism for intraocular pressure reduction. Crippling arthritis led him to develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously.

Why this matters for Terrell County: Every pet owner in Terrell County understands this moment. Whether you’re in Dawson or out in the rural stretches, your dog or cat isn’t just an animal—they’re family. When the vet says there’s nothing left to do, you’ll try anything. Bentley’s story gives you hope, but more importantly, it gives you proof that cannabinoids work in a way that can’t be faked. That decade of formulation development for one dog is why our RSO has seven cannabinoids instead of one. Bentley was our R&D lab, and his life depended on getting it right.

Multi-cannabinoid synergy—single cannabinoids weren’t enough

Single cannabinoids were not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. CBD alone could not address neurodegeneration and dementia and glaucoma and arthritis simultaneously. Minor cannabinoids like CBG, CBN, and CBC became critical as Bentley aged. Pharmaceutical precision mattered—Bentley’s life depended on formula accuracy, not guesswork.

Why this matters for Terrell County: If you’re dealing with multiple health issues—maybe chronic pain and anxiety and sleep problems—you know that a single pill doesn’t fix everything. The same is true for cannabinoids. Our seven-cannabinoid approach means you’re getting a formula designed for complexity, not simplicity. For the folks in Terrell County facing the kind of multifaceted health challenges that come with aging, manual labor, and limited healthcare access, that complexity is exactly what you need.

Colin also knows pharmaceutical dependence personally

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey—a feat that is notoriously difficult and dangerous—using the cannabinoid knowledge he had developed keeping Bentley alive. The Peace Gummies formula that became an OilWell product was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, OilWell also offers the Peace Gummies formula in a vape form, which Colin personally uses to manage his insomnia and severe PTSD on an ongoing basis. This is not theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills do not.

Why this matters for Terrell County: We know that prescription pill problems have hit rural Georgia hard. Whether it’s pain pills after a farming injury, anxiety meds when the stress gets too much, or sleep aids that stop working—many folks in Terrell County have been down that road. Colin’s personal experience with benzo withdrawal isn’t just a story—it’s the reason our Peace Gummies exist. He needed something that worked when Xanax didn’t, and he built it from the same cannabinoid knowledge that went into our RSO.

Formulas used by doctors—Crohn’s, IBS, PTSD, vegans, diabetics

Over time, the therapeutic benefits of cannabis that Colin first discovered through his efforts to save Bentley became the core of his work. He has developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. His focus has always been on making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

Why this matters for Terrell County: In a county where diabetes rates run higher than the national average, where digestive issues are common but specialists are scarce, having formulations that doctors actually use is significant. If you’re a vegan in Terrell County, you know how hard it can be to find products that fit your lifestyle. If you’re diabetic, you need to know exactly what’s in what you’re taking. Our formulas are designed for real-world complexity, not theoretical simplicity.

ABC13 featured Colin in seven news segments

ABC13 KTRK Houston—Houston’s number-one news source—featured Colin Valencia and OilWell Cannabis in seven comprehensive news segments spanning 2019 to 2023, covering Texas marijuana law, Delta-8 legal analysis, COVID-19 community health leadership, criminal justice reform, and cannabis business pioneering. Colin was repeatedly selected as the primary industry expert for cannabis policy and product coverage in America’s fourth-largest city.

Why this matters for Terrell County: Houston is a long way from Terrell County, but mainstream media validation from a major-market ABC affiliate is a credibility signal that travels. When you’re in Terrell County trying to figure out who to trust in the confusing world of cannabis products, knowing that a major news organization vetted Colin’s expertise over seven separate features over four years is a powerful trust indicator. This isn’t self-promotion—it’s independent verification.

Colin’s 2019 foundational quote

Colin’s quote from the first ABC13 feature in September 2019 captures the OilWell philosophy: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

Current operations—Montrose/Houston, revenue, Google rating, DSHS license

Today, OilWell Cannabis operates from Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). The company has been operating since 2019, generates approximately one million dollars in annual revenue, maintains a near-5.0 Google rating, and is Texas DSHS licensed. OilWell’s products are not mass-produced—they are carefully crafted with a personal touch, from the artwork on the packaging to the formulations inside. All artwork, formulations, and packaging are created in-house in Houston, using only OilWell’s own recipes and ideas. Colin brings Houston grit, McAllen roots, and a builder’s mindset to the company, but the posture stays simple: make products with intent, answer directly, and never pretend cannabis is right for everyone.

Why this matters for Terrell County: We can’t be physically present in Terrell County—we’re based in Houston—but our shipping infrastructure means we can get product to you just as reliably as any company based in Atlanta or Columbus. Our Google rating and DSHS license are verifiable trust signals you can check yourself. We’re not a fly-by-night operation. We’re a real business with real accountability.

The OilWell RSO philosophy

OilWell’s RSO is not traditional Rick Simpson Oil. It is a formulated, multi-cannabinoid product informed by the RSO tradition but departing from it in ways that are deliberate, evidence-motivated, and designed to solve the problems that limited Rick Simpson’s original vision.

Four core principles define OilWell’s approach, each aligning with and evolving Simpson’s original ethos:

1. Accessibility over gatekeeping. No medical card is required. Anyone age twenty-one or older can purchase. OilWell ships nationwide across the United States and internationally to customers who verify local legality. Simpson believed medicine should be accessible to everyone; OilWell built a product and distribution model that makes that accessible legally.

2. Patient-controlled potency. THCa is sold in its acidic, non-psychoactive form. The customer decides whether to use it raw for non-psychoactive benefits or to decarboxylate it into delta-9 THC for full psychoactive potency. Simpson believed patients should control their own medicine; OilWell engineered a product that puts that control in the customer’s hands through chemistry rather than rhetoric.

3. Open-source formulas. OilWell publishes their complete formulas publicly—every cannabinoid, every milligram amount, every percentage—so that anyone who cannot afford the product can source ingredients and make their own version. Simpson gave his oil away for free and taught people how to make it; OilWell adapted that ethos for the modern cannabinoid marketplace by selling a professionally manufactured product and publishing the recipe.

4. Evidence-informed, not evidence-overstating. The GENERAL KNOWLEDGE section in this document represents OilWell’s commitment to honest education about what the science actually says. Simpson operated without access to peer-reviewed literature or clinical trial data; OilWell has that access and uses it to distinguish between what is well-supported, what is emerging, and what is overstated.

Farm Bill compliance and the THCa legal framework

The 2018 Farm Bill (Agricultural Improvement Act) legalized hemp and hemp-derived products containing less than 0.3 percent delta-9 THC by dry weight at the federal level in the United States. This legal framework is the foundation of OilWell’s RSO product design.

OilWell’s RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle—3 milligrams per milliliter—well under the 0.3 percent threshold. All cannabinoids in the formula are hemp-derived. The product is legal under federal law and in most states.

THCa—tetrahydrocannabinolic acid—is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at the point of sale because it has not been converted to delta-9 THC.

The practical significance of this framework is substantial. The customer can decarboxylate THCa into delta-9 THC at home by heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container. This converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC in the formula, this produces approximately 1,405 milligrams of total delta-9 THC—giving the product psychoactive potency comparable to traditional illegal RSO, entirely at the customer’s discretion after purchase.

This means the same product can function as a non-psychoactive anti-inflammatory (used raw) or as a full-potency psychoactive cannabinoid product (after home decarboxylation). The customer controls the decision. The product is legal everywhere all component cannabinoids are legal, which enables international shipping to jurisdictions where hemp-derived products with less than 0.3 percent delta-9 THC are permitted.

Why this matters for Terrell County: Georgia’s medical cannabis program is one of the most restrictive in the country. Unless you have one of a very few qualifying conditions and can find a doctor registered with the program, you can’t access legal THC products in Georgia. But the Farm Bill created a pathway for hemp-derived products. Our RSO is legal to purchase, possess, and ship to Terrell County because it contains less than 0.3% delta-9 THC at the point of sale. The THCa in the bottle is your legal pathway to therapeutic THC levels—if you choose to activate it. This is the most significant legal cannabis access innovation in modern history, grounded in chemistry, not loopholes.

THCa conversion—decarboxylation at home yields ~1,405mg total delta-9

The conversion chemistry: THCa has a molecular weight of 358.47 g/mol. The conversion ratio is approximately 1 milligram THCa = 0.877 milligrams delta-9 THC after decarboxylation, reflecting the loss of a CO₂ molecule during the reaction.

Important legal notice: THCa converts to delta-9 THC when heated. Customers are responsible for understanding and complying with their local laws regarding cannabinoid products. OilWell ships with full documentation, Certificates of Analysis, and receipts. International customers accept all customs and legal risk. The customer is responsible for verifying legality in their jurisdiction and accepts all customs and legal responsibility.

Open-source formulas—why OilWell publishes everything

OilWell publishes their complete RSO formulas—every cannabinoid, every milligram amount, every percentage—in public documents including this one. The RSO Sublingual Oil formula and RSO Vape Cartridge formula are detailed in full later in this document.

The rationale is straightforward: if someone cannot afford OilWell’s products—$129.99 for the sublingual oil, $49.99 for the vape cartridge—they can see exactly what the formula contains, source the individual cannabinoid distillates and isolates, and make their own version. The formulas in the RSO Sublingual Oil and RSO Vape Cartridge sections of this document are the open-source formulas.

This is a direct echo of Rick Simpson’s original ethos. Simpson gave his oil away for free and taught people how to make it. He never patented his method. He never charged patients. OilWell adapted that ethos for the modern cannabinoid marketplace: they sell a professionally manufactured, lab-tested, standardized product for those who want it, and they publish the complete recipe for those who want to make it themselves.

As Colin Valencia said on ABC13 in 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

CBD golden paste recipe for pets—the original open-source formula

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1 to 2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on the size and needs of the pet; consult with a veterinarian)

Instructions:

1. Mix the turmeric and water. In a saucepan, combine the turmeric powder and water, stirring over low heat. Stir continuously until it forms a thick paste. This should take about 7 to 10 minutes. Add a little more water if it becomes too thick.
2. Add the coconut oil and pepper. Once you have a thick paste, add the coconut oil and freshly ground black pepper. Stir until all ingredients are thoroughly mixed.
3. Cool and store. Allow the paste to cool, then transfer it to a jar with a lid. Store it in the refrigerator for up to two weeks.
4. Dosage. Add a small amount of CBD oil to the paste before giving it to the pet, adjusting the dosage based on their weight and health needs. Start with a low dose and gradually increase as needed.

Serving suggestion: Mix a small amount of the golden paste with the pet’s food once or twice a day. Monitor the pet for any changes and consult with a veterinarian if there are any concerns. Always consult with a veterinarian before starting any new supplement regimen for a pet.

Why this matters for Terrell County: This recipe—published for free, years before the RSO formulas were open-sourced—demonstrates that the pattern is consistent. Colin gave away the formula that saved Bentley before he gave away the formula designed for people. The open-source ethos is not a marketing strategy. It is the foundational behavior of the company. If you’re in Terrell County and you have a pet in crisis, you can make this today with ingredients from the local grocery store. That’s not theory—that’s action.

The decarboxylation choice—patient-controlled potency

Traditional RSO was always fully decarboxylated. The heat of solvent evaporation converted all THCa into delta-9 THC, leaving the patient with no choice about psychoactivity—the oil was always psychoactive.

OilWell’s sublingual formula contains 1,500 milligrams of THCa in its acidic, non-psychoactive form. This creates three distinct usage options for the customer:

Option 1—Raw, no heat. All 1,500 milligrams stays as THCa—completely non-psychoactive. The THCa evidence profile in the GENERAL KNOWLEDGE section describes potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism. This option is compatible with work, driving, and daytime use with zero psychoactive impairment.

Option 2—Fully activated, home decarboxylation. Heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC already in the formula, this yields approximately 1,405 milligrams of total delta-9 THC. Combined with 6,000 milligrams of delta-8 THC, the activated product achieves psychoactive potency comparable to traditional high-THC RSO—100 percent legally, because decarboxylation occurs at the customer’s discretion after purchase. The customer may also transfer a controlled portion of the oil from the original bottle into a second empty oven-safe glass container, decarboxylating only what they intend to use and preserving the remainder in its raw THCa form.

Option 3—Vape, auto-decarboxylation. The RSO Vape Cartridge vaporizes at 400 to 450°F, which instantly converts THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. This is the fastest-onset RSO delivery method available.

Solvent-free production

OilWell’s RSO is not an extraction product in the traditional sense. It is a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in a controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents are present in the finished product.

This approach eliminates the residual solvent risk that is one of the most significant safety concerns with traditional RSO production, as discussed in the Rick Simpson section of this document.

The product uses organic MCT oil (medium-chain triglycerides) as the carrier base. MCT oil is a food-grade lipid carrier that facilitates cannabinoid absorption through sublingual tissue and provides a neutral taste profile—a significant improvement over the tar-like consistency and solvent-residual odor of traditional RSO.

Third-party lab testing covers cannabinoid potency, terpene profile, and safety panels including pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request and accessible through the OilWell website.

The broader OilWell product portfolio

Beyond RSO, OilWell Cannabis produces a range of cannabinoid products, each developed from the formulation knowledge Colin built over Bentley’s ten-year journey and his own experience with PTSD and benzo withdrawal.

Asshole Peach—OilWell’s most popular product. Asshole Peach is a carefully formulated experience designed to provide a euphoric, long-lasting sensation. It is particularly favored by veterans for its ability to relieve pain and PTSD symptoms without being overly aggressive.

Peace Gummies—Developed directly from Colin’s own experience with PTSD and benzodiazepine addiction. Peace Gummies helped him quit Xanax cold turkey. The formula is also available in a vape form for quick relief—Colin personally uses the vape to manage his insomnia and severe PTSD on an ongoing basis.

Custom creations—OilWell offers custom-made products tailored to the specific needs of individual customers. Whether it involves specific cannabinoid ratios, particular delivery formats, or formulations for unique health circumstances, OilWell designs targeted products on request. This includes formulations for vegans, diabetics, and those with specific dietary or health needs.

Two product formats

OilWell offers the RSO formula in two delivery formats, each designed for different use cases and pharmacokinetic profiles.

RSO Sublingual Oil—$129.99

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15 to 45 minutes (sublingual absorption through oral mucosa)
• Peak effects: 1 to 2 hours
• Duration: 4 to 6 hours
• Bioavailability: 13 to 19 percent (sublingual route partially bypasses first-pass liver metabolism)
• Approximately 40 to 60 doses per bottle depending on serving size

RSO Vape Cartridge—$49.99

• 1-gram cartridge
• 900 mg+ total cannabinoids
• Same six-cannabinoid ratio as sublingual formula
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1 to 2 minutes (fastest cannabinoid delivery method)
• Peak effects: 10 to 15 minutes
• Duration: 2 to 4 hours
• Bioavailability: 10 to 35 percent (variable, dependent on inhalation technique)
• Automatic THCa decarboxylation at vaping temperature (400 to 450°F)

When to use each format

Use case	Recommended format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration
Maximum bioavailability	Sublingual	13-19% absorption
Portability and discretion	Vape	Compact, no measuring required
Precise dosing control	Sublingual	Graduated dropper in 0.1 mL increments
Daytime non-psychoactive use	Sublingual (raw, no heat)	THCa stays inactive, zero impairment
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC

Why this matters for Terrell County: If you’re working the fields from dawn to dusk, you need daytime relief without impairment. That’s the raw sublingual option. If you’re dealing with breakthrough pain that hits suddenly, you need fast relief. That’s the vape. If you need sleep through the night, you need sustained release. That’s the decarbed sublingual. One formula, three ways to use it, depending on what your day in Terrell County looks like.

Competitive comparison—OilWell RSO vs. alternatives

The following tables present factual comparisons between OilWell’s RSO formula and other RSO products available on the market. These comparisons are based on publicly available product specifications and are presented for informational context.

OilWell RSO vs. Texas TCUP dispensary RSO (e.g., Texas Original)

Dimension	TCUP dispensary RSO	OilWell RSO
Cannabinoid profile	THC-only (approx. 420 mg THC per 0.5 g syringe)	7 cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC
CBG content	0 mg	3,000 mg
CBN content	0 mg	750 mg
CBC content	0 mg	750 mg
Patient-controlled potency	No—always fully psychoactive	Yes—THCa non-psychoactive until heated by customer
Access requirements	TCUP medical card with qualifying condition	Age 21+ only, no medical card required
Qualifying conditions	Cancer, PTSD, epilepsy, autism, terminal illness, ALS, MS, seizure disorders, incurable neurodegenerative diseases	None required
Delivery	Must travel to physical dispensary location	Same-day delivery Houston, nationwide and international shipping
Farm Bill compliant	No—state medical cannabis program	Yes—less than 0.3% delta-9 THC

OilWell RSO vs. hemp CBD RSO (e.g., Lazarus Naturals)

Dimension	Lazarus Naturals RSO (10 mL, 1,000 mg)	OilWell RSO (30 mL, 16,590 mg)
Total cannabinoids	1,000 mg	16,590 mg
CBD content	Approximately 950 mg	4,500 mg
CBG content	15.5 mg	3,000 mg
CBN content	0.7 mg	750 mg
Delta-8 THC	0 mg	6,000 mg
THCa (convertible to delta-9 THC)	Minimal	1,500 mg (converts to approximately 1,315 mg delta-9 THC)
Psychoactive option	No meaningful psychoactive effect	Yes—via THCa decarboxylation and delta-8 THC
Approximate price	$40 to $50	$129.99

OilWell RSO vs. traditional illegal RSO—This comparison is presented in the Traditional RSO vs. modern formulated RSO table in the ABOUT RICK SIMPSON section above. Refer to that table for the full eleven-dimension comparison.

Why these comparisons matter for Terrell County: If you’re in Terrell County, you can’t walk into a dispensary and compare products side by side. Georgia doesn’t have that infrastructure. These tables let you see exactly how OilWell stacks up against what’s available in states that do have legal programs, and against the CBD-only products you might find at a local shop in Albany or Columbus. The numbers speak for themselves: 16,590 mg of total cannabinoids is more than most products on the market. The seven-cannabinoid profile is more comprehensive. The patient-controlled potency is unique. And the no-medical-card-required access is essential for Georgia residents.

Condition-specific usage context

Important disclaimer: The following usage contexts are informed by cannabinoid research cited in the GENERAL KNOWLEDGE section of this document and by OilWell’s formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not a substitute for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have any health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Chemotherapy-related nausea and appetite support

• Pre-chemo: 0.5 to 1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2 to 3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0 to 2.0 mL sublingual before bed (delivers 25 to 50 mg CBN)

Chronic pain (fibromyalgia, arthritis, neuropathy)

• Daytime: 0.3 to 0.5 mL raw sublingual—provides anti-inflammatory cannabinoid exposure without psychoactive impairment
• Nighttime: 0.5 to 1.0 mL decarboxylated sublingual—combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset

Sleep support

• Before bed: 1.0 to 2.0 mL sublingual
• At 2.0 mL, this delivers 50 mg CBN—the dosage level investigated in the 2024 sleep literature
• At 1.0 mL, this delivers 25 mg CBN—above the 20 mg threshold associated with reduced sleep disturbance in published research

Anxiety and stress

• Daytime functional relief: 0.3 mL raw sublingual—CBD and CBG address anxiety-related pathways without psychoactive impairment
• Nighttime: 1.0 mL sublingual—full cannabinoid profile including CBN for sleep architecture

General titration principle: Start low, go slow. Begin with 0.25 to 0.5 mL sublingual and assess effects over 2 to 3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors.

Why this matters for Terrell County: If you’re dealing with these conditions in Terrell County, you probably already know the limitations of the local healthcare system. These dosing guidelines give you a starting point for conversations with your doctor—whether you’re seeing a primary care physician in Dawson or making the trip to a specialist in Albany or Columbus. They’re not prescriptions, but they’re evidence-informed starting points that respect your autonomy while keeping safety front and center.

Delivery and global accessibility

OilWell operates the only same-day RSO delivery system in Houston. Beyond Houston, the company ships nationwide and internationally.

Houston same-day delivery

Zone	Coverage	Delivery fee	Typical turnaround
Texas Medical Center	All 60+ TMC institutions (MD Anderson, Memorial Hermann, Methodist, Texas Children’s, St. Luke’s, and more)	FREE	2 to 4 hours
Inner Loop (610)	Downtown, Midtown, Montrose, Heights, Rice Village, Museum District, River Oaks, Upper Kirby, Galleria	$5	2 to 4 hours
Within Beltway 8	Bellaire, Memorial, Spring Branch, South Houston, Pasadena (partial), Hobby Airport area	$10	3 to 5 hours
Greater Houston suburbs	Katy, Sugar Land, Pearland, Clear Lake, Woodlands, Cypress, Tomball, Humble, Kingwood	$15	4 to 6 hours
Extended region (60 miles)	Galveston, Baytown, Rosenberg, Conroe, La Porte, Seabrook	$20 to $25	Same-day if ordered before 2 PM

Free delivery to the Texas Medical Center—the world’s largest medical complex with over 10 million patient visits annually—reflects OilWell’s commitment to accessibility for the patients who need it most.

Nationwide shipping

• All 50 states where Farm Bill-compliant products are legal
• USPS Priority Mail (2 to 3 business days), FedEx and UPS Ground (3 to 5 business days)
• Discreet packaging with no cannabis branding visible
• Tracking provided for all orders
• Temperature-stable packaging for summer shipments
• Signature-required option available

International shipping

OilWell ships internationally and has already delivered to multiple countries across multiple continents. The THCa legal framework makes this possible: because the product contains less than 0.3 percent delta-9 THC at the point of sale, it meets the definition of a hemp-derived product under the 2018 Farm Bill and is shippable to jurisdictions with compatible hemp laws.

• All international packages include full documentation, Certificates of Analysis (COAs), and receipts for customs purposes
• Minimum flat-fee shipping applies; excessive international shipping costs are billed to the customer
• The customer is responsible for verifying legality in their jurisdiction and accepts all customs and legal risk

Why this matters for Terrell County: We can’t offer same-day delivery to Terrell County—Houston is too far away. But we can offer nationwide shipping that gets to you in 2-3 days via USPS Priority Mail. For a rural county where the nearest cannabis retailer might be hours away, that accessibility is crucial. You can order from your home in Dawson or the outskirts of Sasser and have a professionally manufactured, lab-tested product delivered discreetly to your door. No driving to Atlanta. No searching for a local shop that might not have what you need. Just reliable, legal access.

How the OilWell formulas connect to the evidence in this document

Every cannabinoid in OilWell’s formula—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—has its own evidence profile in the GENERAL KNOWLEDGE section of this document. Every terpene in OilWell’s formula—limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—is covered with preclinical and review-level evidence.

The formulas published later in this document are not standalone product listings. They are anchored to per-compound evidence summaries that explain what is well-supported by human clinical data, what is emerging, and what is overstated. Where OilWell’s RSO guide page makes specific research claims about individual cannabinoids or terpenes, this document provides the source evaluation context—the same peer-reviewed citations, the same evidence-tier assessments, and the same cautious interpretation framework.

The GENERAL KNOWLEDGE section’s evidence hierarchy, overstatement warnings, and safety notes apply equally to OilWell’s own products. This document does not exempt OilWell from the same evidence standards applied to the broader cannabinoid field. That is intentional. OilWell’s position—as stated by Colin Valencia in 2019—is that people deserve the best possible version of the information so they can give it a fair shot and decide for themselves whether it is right or wrong for them. This document is the research foundation for that position.

OilWell Cannabis is more than a brand—it is a promise to its customers that it will always strive to deliver the best, most thoughtful cannabis products available. OilWell is not here to follow trends. It is here to set them. And as the company continues to grow, the focus remains on maintaining the same level of integrity, creativity, and commitment that has defined it from the day Bentley got up, walked across the room, and brought his ball to play.

MEDIA RECOGNITION AND COMMUNITY IMPACT

Colin Valencia—Houston’s go-to cannabis authority

Between September 2019 and April 2023, ABC13 Houston (KTRK)—the ABC affiliate serving the fourth-largest city in the United States—featured Colin Valencia and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different ABC13 reporters sought Colin out across those years: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers. No other Houston cannabis operator appears with that frequency or across that breadth of subject matter during the same period.

The features document a consistent pattern. When ABC13 needed to explain a new cannabis product to its audience, it called Colin. When a state agency reversed course on Delta-8 legality overnight, it called Colin. When a sitting president announced marijuana pardons and the station needed someone who had personally lived with a cannabis conviction to put it in context, it called Colin. When the station wanted to tell the story of a growing industry on 4/20, it was Colin’s hemp field and Colin’s voice that anchored the report.

What follows is a complete, chronological record of each feature—every quote preserved exactly as published, every contextual detail documented, every connection to the broader OilWell story and mission noted, and the full article content from each ABC13 report preserved for reference.

Why this matters for Terrell County: Houston’s media market might seem far away, but in the digital age, credibility travels. When you’re in Terrell County trying to vet a company you’ve only found online, seeing that company featured seven times on a major ABC affiliate over four years is a powerful signal. It’s not a paid advertisement—it’s editorial judgment by professional journalists who repeatedly chose Colin as their expert source.

Feature: Texas CBD businesses booming as industry continues to evolve—September 15, 2019

Source: ABC13 Houston (KTRK)
Headline: “Texas CBD businesses booming as industry continues to evolve”
Reporter: Tom Abrahams
Published: Sunday, September 15, 2019

Full article content (abridged for relevance):

HOUSTON, Texas (KTRK) — You can spot the signs in almost any neighborhood. CBD has turned into a booming business over the past few months, with entrepreneurs pitching the product for every member of the family, even the pets.

Colin Valencia, who runs OilWell CBD, a local wholesaler, says it’s an evolving industry.

“It’s a lot of educating people, but not over-promising people. I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”
— Colin Valencia, OilWell CBD

Why this matters for Terrell County: This 2019 quote is the foundation of everything we do. It’s the promise we make to every customer in Terrell County: no snake oil, no false hope, just honest information and the best product we can make. That commitment hasn’t changed in four years of media coverage.

Feature: Entrepreneur creates direct-to-consumer business ahead of marijuana decriminalization efforts—March 22, 2021

Source: ABC13 Houston (KTRK)
Headline: “Entrepreneur creates direct-to-consumer business ahead of marijuana decriminalization efforts”
Reporter: Tom Abrahams
Published: Monday, March 22, 2021

Key quote:

“People think that everyone just wants to get high and it’s about giggling and things like that, and there’s nothing wrong with that. But that’s a different version of therapy, and people are looking for things to help them with real pain. Pain comes in a lot of different forms.”
— OilWell CBD’s Colin Valencia

Feature: What is Delta 8 THC and why is it considered legal weed in Texas—May 24, 2021

Source: ABC13 Houston (KTRK)
Headline: “What is Delta 8 THC and why is it considered ‘legal weed’ in Texas?”
Reporter: Steve Campion
Published: Monday, May 24, 2021

Key exchange:

Steve Campion (ABC13): “Why would someone want to smoke that?”

Colin Valencia: “I don’t give a sh** if it’s wrong to say you’ll get high off it. Maybe you want to get high.”

Why this matters for Terrell County: That uncensored honesty on mainstream TV is a trust signal. Colin said the quiet part out loud—that sometimes people want the psychoactive effects for therapy—and ABC13 aired it. That’s the kind of transparency you need when you’re making decisions about cannabis in a conservative state like Georgia.

Feature: Houston CBD shop giving away free products to those who get COVID vaccine—August 20, 2021

Source: ABC13 Houston (KTRK)
Headline: “Houston CBD shop giving away free products to those who get COVID vaccine”
Reporter: KTRK Staff
Published: Friday, August 20, 2021

Key details:

• OilWell gave away 1,000 special edition caviar pre-rolls (valued at $34.99 each = approximately $35,000 in product) to encourage COVID-19 vaccination
• The giveaway was hosted at HydroShack Hydroponics in The Heights
• OilWell coordinated with the city of Houston to amplify the effort

Why this matters for Terrell County: This wasn’t marketing—this was documented community health action. During a public health crisis, OilWell committed $35,000 in product to help people get vaccinated. That’s the kind of values-driven leadership that matters when you’re choosing which company to support.

Feature: Texas ban over once legal hemp product Delta 8 raises questions over legality—October 19, 2021

Source: ABC13 Houston (KTRK)
Headline: “Texas’ ban over once legal hemp product, Delta 8, raises questions over legality”
Reporter: Shelley Childers
Published: Tuesday, October 19, 2021

Key details:

• Colin proactively removed all Delta-8 products from shelves before enforcement began
• He warned other operators who were unknowingly shipping Schedule I narcotics
• Texas DSHS stated Delta-8 “has always been illegal” but couldn’t explain why the market was allowed to thrive
• Zachary Maxwell noted veterans with PTSD used these products, and a single vape cartridge could mean felony charges

Why this matters for Terrell County: This feature demonstrates ethical leadership during a regulatory crisis. Colin absorbed a major revenue loss to act ethically and protect customers. That’s the kind of company you can trust when you’re in a legally ambiguous situation like Georgia’s cannabis landscape.

Feature: Biden marijuana pardon—experts weigh in on why Texas won’t see impact—October 7, 2022

Source: ABC13 Houston (KTRK)
Headline: “Experts weigh in on why Texas won’t see impact in accordance with Biden’s pardon announcement”
Reporter: Nick Natario
Published: Friday, October 7, 2022

Key revelation:

• Colin revealed he has previously faced charges for marijuana possession
• OilWell was preparing to debut a CBD vending machine
• Legal expert noted the pardon only applies to federal convictions, not state-level arrests (Texas had 300,000 marijuana-related arrests vs. 6,500 federal pardons)

Why this matters for Terrell County: This is the most personal dimension of Colin’s story. He doesn’t just understand cannabis criminalization intellectually—he’s lived it. That personal experience with the criminal justice system makes every other quote about education and integrity more powerful.

Feature: Marijuana industry getting creative as Texas laws continue to change—April 21, 2023

Source: ABC13 Houston (KTRK)
Headline: “‘I want it to be legalized’: Marijuana industry getting creative as Texas laws continue to change”
Reporter: Nick Natario
Published: Friday, April 21, 2023

Key quote:

“Right now is actually a pretty – like Renaissance – pretty important time that should be enjoyed now.”
— Colin Valencia

Why this matters for Terrell County: The “Renaissance” framing is about opportunity. While Georgia’s laws remain restrictive, the Farm Bill created a window for legal hemp-derived products. This is the time to access these compounds legally, before regulations potentially tighten. For Terrell County residents, that window is open now.

Complete index of all Colin Valencia quotes across all ABC13 features

Chronological order:

1. “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.” (Sept 2019)

2. “Pain comes in a lot of different forms.” (March 2021)

3. “I don’t give a sh** if it’s wrong to say you’ll get high off it. Maybe you want to get high.” (May 2021)

4. “We just want Houston to be as healthy as possible. We’re not doctors. We’re not experts on this . We don’t have any political agenda.” (Aug 2021)

5. “[We’re] trying to get the city behind me to help as many people as we can. I really want to help things.” (Aug 2021)

6. “It’s going to be a surprise to a lot of people.” (Oct 2021)

7. “It was a prime seller and a prime interest of customers, and they really enjoyed the benefits of it.” (Oct 2021)

8. “So those people are now, because they didn’t know, shipping Schedule 1 narcotics, and people are receiving it.” (Oct 2021)

9. “It’s disappointing, but I’m not going to lose my customers and business are going to want our expertise on how to continue thriving in the industry.” (Oct 2021)

10. “You face challenges with housing, loans, and banking, I mean with about everything.” (Oct 2022)

11. “I would love to see people not get hurt for this anymore.” (Oct 2022)

12. “I want it to be legalized. I’m just saying that’s a very hyped conversation. If you really look at what’s here now, there’s nothing you could show me that I could accomplish with what literally we have right now.” (April 2023)

13. “Right now is actually a pretty – like Renaissance – pretty important time that should be enjoyed now.” (April 2023)

Key facts and details from the media record

About Colin Valencia and OilWell Cannabis:

• Colin Valencia is the owner of OilWell Cannabis (also referred to as OilWell CBD in earlier articles)
• He has previously faced charges for marijuana possession (revealed in the October 2022 Biden pardon feature)
• The OilWell dispensary is located in southwest Houston
• OilWell specializes in hemp-derived CBD and THC products
• OilWell was described as a local wholesaler in 2019 (earliest feature)
• By 2022, OilWell was preparing to debut a CBD vending machine (Biden pardon feature)
• OilWell products were sold at HydroShack Hydroponics on West 20th Street in The Heights
• OilWell partnered with The Game on special edition Delta-8 caviar comet rock pre-rolls (COVID vaccine feature)
• OilWell gave a lift to Jonathan Pina’s High Maintenance Edibles mobile vendor concept (decriminalization feature)
• OilWell gave away 1,000 special edition caviar pre-rolls (valued at $34.99 each = approximately $35,000 in product) to encourage COVID vaccination
• OilWell contacted the city of Houston to help coordinate vaccination efforts
• Colin proactively removed all Delta-8 products from shelves when the ban was announced and tried to spread the word to other operators who were unknowingly shipping Schedule I narcotics

ABC13 reporters list and timeline

Reporters who covered OilWell:

1. Tom Abrahams—September 2019 and March 2021
2. Steve Campion—May 2021
3. KTRK Staff—August 2021
4. Shelley Childers—October 2021
5. Nick Natario—October 2022 and April 2023

Timeline of features (chronological):

1. September 15, 2019—CBD Business Boom
2. March 22, 2021—Decriminalization/Jonathan Pina
3. May 24, 2021—Delta-8 THC “Legal Weed”
4. August 20, 2021—COVID Vaccine Giveaway
5. October 19, 2021—Delta-8 Ban Impact
6. October 7, 2022—Biden Marijuana Pardon
7. April 21, 2023—Texas Marijuana Laws 4/20 Special

The through-line—what the media record reveals

Taken together, these seven ABC13 features tell a story that no single article could capture on its own.

Consistency across years. Colin appeared on ABC13 in 2019, 2021 (four times), 2022, and 2023. Through every shift in the legal landscape, ABC13 returned to Colin as a primary source.

Breadth of expertise. The features span business reporting, consumer health education, product investigation, legal analysis, political commentary, and community health advocacy. No other Houston cannabis figure was asked to speak to that range of topics.

Community action. The COVID vaccine giveaway—$35,000 in product, coordination with city government, no political strings—is documented evidence of the community-first philosophy.

Personal stakes. The October 2022 revelation that Colin has a personal marijuana conviction history transforms the entire media record. He doesn’t just understand the issues intellectually—he’s lived them.

Evolution of language. From “local wholesaler” in 2019 to industry authority in 2023, the media record tracks the growth of both the business and its founder’s public role.

These features are not marketing materials. They are independently produced, editorially controlled news segments from a major-market ABC affiliate that repeatedly identified Colin Valencia as the most credible, most quotable, and most accessible voice in Houston’s legal cannabis industry. That is the kind of recognition that cannot be purchased—it can only be earned.

GENERAL KNOWLEDGE

Research method and evidence weighting

This section prioritizes sources in the following order: human clinical evidence, systematic reviews and meta-analyses, NIH and other institutional summaries, then mechanistic or preclinical literature when human data are sparse. That weighting matters here because the evidence base is not evenly distributed. Of the compounds listed in this document, CBD and delta-9 THC have the strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes are still much more dependent on reviews, animal work, in vitro pharmacology, or early translational literature.

Institutional baseline from NIH and related sources

• NCCIH states that the strongest established cannabinoid evidence is for certain rare epilepsies, chemotherapy-related nausea and vomiting, and appetite or weight-loss indications associated with HIV/AIDS. It also notes only modest evidence for chronic pain and multiple-sclerosis-related symptoms, with many other claimed uses still in early-stage research.
• NCCIH also emphasizes that the FDA has not approved the cannabis plant itself for medical use, although purified CBD and synthetic THC-like drugs have specific approvals.
• Safety concerns repeatedly highlighted by NIH and institutional sources include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy-related concerns, accidental pediatric exposure, contamination or labeling inaccuracy, and THC-vape lung-injury concerns.
• NCCIH specifically warns that over-the-counter CBD products may differ from their labels and that CBD itself has been associated with decreased alertness, gastrointestinal effects, liver-related adverse effects, and drug interactions.

Cannabinoids

CBD

• Evidence profile: strongest human evidence in the current formula set, especially when CBD is studied as a purified product rather than as a loose wellness ingredient.
• What is best supported: purified CBD has the most credible human evidence in seizure disorders, and this is the clearest major-example indication acknowledged by institutional and peer-reviewed literature.
• Anxiety research: a 2024 systematic review and meta-analysis covering 316 participants across eight eligible articles reported a statistically significant anxiolytic signal, but the authors also stressed that the clinical sample remains limited and that more trials are needed before broad conclusions are justified.
• Pain research: a 2024 systematic review of clinical and preclinical CBD monotherapy studies concluded that the pain literature is promising but heterogeneous, with trial quality and consistency still limiting confidence in broad analgesic claims.
• Sleep research: a 2023 insomnia review found that the literature remains methodologically weak, with many studies relying on nonvalidated subjective measures and relatively few objective sleep assessments.
• Safety and interaction concerns: a 2023 systematic review and meta-analysis found a real signal for liver enzyme elevation and possible drug-induced liver injury in some CBD contexts, which is especially relevant for concentrated oral products and polypharmacy settings.

CBG

• Evidence profile: mostly review-level and preclinical; human evidence remains sparse.
• Pharmacology: CBG is the biosynthetic precursor to several major cannabinoids and appears pharmacologically distinct from both THC and CBD. Review literature describes interactions spanning cannabinoid receptors as well as alpha-2 adrenoceptors and 5-HT1A-related signaling, which makes it mechanistically interesting but not yet clinically established.
• Potential research areas: published reviews discuss possible relevance to neurologic disorders, inflammatory bowel disease, and antibacterial activity, but these are primarily pharmacology-led hypotheses or preclinical findings rather than mature human therapeutic conclusions.
• Caution: one of the key points from the 2021 pharmacology review is that CBG is already being sold commercially while the evidence base remains thin, which means claims frequently outrun the science.

Delta-8 THC

• Evidence profile: pharmacologically relevant, psychoactive, and much less clinically characterized than delta-9 THC.
• Comparative pharmacology: a 2022 review concluded that delta-8 THC and delta-9 THC have broadly similar pharmacokinetic and pharmacodynamic behavior. Delta-8 THC is a partial CB1 agonist with cannabimimetic activity in animals and humans, but it appears less potent than delta-9 THC, likely in part because of weaker CB1 affinity.
• Public-health literature: a 2023 scoping review found that much of the delta-8 evidence base is still dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong modern human trials. The same review also noted reports of adverse consequences and emphasized regulatory and product-quality concerns.
• Manufacturing context: the recent chemistry and pharmacology review reinforces that commercial delta-8 interest is tied to greater stability and easier synthesis relative to naturally scarce plant levels, which is part of why product-byproduct and lab-testing questions matter.

THCa

• Evidence profile: important chemically and formulation-wise, but still low on direct human therapeutic evidence.
• What it is: THCa is the acidic precursor of THC and may represent a very large share of the THC-related content in raw plant material. The key formulation issue is that THCa decarboxylates into THC during heating and can also change over time during storage and processing.
• Psychoactivity: the major review source stresses that THCa itself does not produce the psychoactive effects associated with THC in humans, but the distinction only holds if the molecule stays in its acidic form and is not substantially decarboxylated.
• Research status: in vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but these are not equivalent to established human outcomes.

Delta-9 THC

• Evidence profile: strongest human evidence of the psychoactive cannabinoids listed here, but also the clearest adverse-effect burden.
• What is institutionally best supported: NCCIH identifies THC-containing cannabinoid medicines as relevant to chemotherapy-related nausea and vomiting, appetite and weight loss in HIV/AIDS, and some multiple-sclerosis- and pain-related outcomes, while still stressing that many other uses remain uncertain or early-stage.
• Pain evidence: a 2022 systematic review of cannabis-based products for chronic pain found that products with high THC content or roughly comparable THC:CBD ratios may provide short-term pain benefit, but they also increased dizziness, sedation, nausea, and treatment discontinuation due to adverse events.
• Pharmacokinetics and onset: classic pharmacokinetic review literature remains useful here: inhaled THC usually produces effects within seconds to minutes, peaks roughly within 15 to 30 minutes, and tapers over a few hours; oral THC has later onset, later peak, and longer duration, which matters for both benefit and overconsumption risk.
• Mental-health risk: a 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis or schizophrenia outcomes and cannabis use disorder, with additional concerning signals for anxiety and depression in nontherapeutic settings.

CBN

• Evidence profile: weak human evidence; marketing has clearly moved ahead of the data.
• What it is often marketed for: sleep and sedation. That reputation is widespread, but the clinical support is far thinner than the market suggests.
• Best direct review for the sleep claim: the 2021 narrative review on CBN and sleep screened 99 human-study abstracts, reviewed eight full-text articles, and found no clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims for CBN.
• Broader sleep literature: the 2024 updated review on cannabis and sleep concluded that overall cannabinoid sleep research still does not match the scale of real-world use, and the need for better-designed, adequately powered trials remains substantial.

CBC

• Evidence profile: emerging, intriguing, and still overwhelmingly preclinical or review-based.
• Pharmacology and therapeutic interest: the 2024 focused review on CBC argues that it has distinct pharmacodynamics, pharmacokinetics, and receptor behavior relative to better-known cannabinoids, and highlights antinociceptive, antibacterial, and anti-seizure areas as especially interesting research targets.
• What the older literature shows: review literature summarizing CBC in animal and in vitro work reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, and possible neurobiological or antiproliferative relevance, but these signals are not yet strong evidence for patient-facing claims.
• Safety caveat: the 2024 CBC review explicitly notes that over-the-counter CBC products are already being sold despite little evidence establishing clinical efficacy or safety.

Terpenes

Terpene claims need even stricter interpretation than cannabinoid claims. Much of the terpene literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models rather than from controlled human studies of cannabis formulations. The 2024 entourage-effect review makes this especially important: terpene bioactivity is plausible and sometimes compelling, but robust proof of clinically meaningful entourage effects in humans remains limited.

Limonene

• Evidence profile: largely review and preclinical, with useful safety literature.
• Potential activity: a 2021 review describes limonene as a multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory, and other possible activities, but the overwhelming share of those claims comes from nonhuman or non-cannabis literature.
• Safety note: limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens and are important in patch-testing literature.

Myrcene

• Evidence profile: mostly preclinical, with very limited human evidence.
• Research summary: the 2021 myrcene review describes anxiolytic, antioxidant, anti-inflammatory, and analgesic properties and discusses possible mechanisms, but explicitly states that human studies are lacking.
• Interpretation caution: myrcene is often invoked in consumer language as if it were a proven sedating terpene that explains couch-lock or sleep effects. That is a stronger claim than the human evidence currently supports.

Caryophyllene

• Evidence profile: among the most mechanistically interesting terpenes because of direct cannabinoid-system relevance, but still mostly preclinical.
• Why it stands out: a 2021 focused review describes beta-caryophyllene as a selective CB2 receptor agonist, which is unusual and makes it especially relevant when discussing cannabis terpenes in pharmacologic rather than purely aromatic terms.
• Research themes: anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective, and related actions are repeatedly discussed in the review literature, but human clinical confirmation remains limited.

Pinene

• Evidence profile: promising preclinical literature, weak human clinical confirmation.
• Brain-health framing: the 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, and neuroprotective signals that justify future study, but it also emphasized that evidence is mostly preclinical and that well-designed clinical trials are lacking.
• Interpretation caution: claims that pinene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts.

Linalool

• Evidence profile: similar to pinene: substantial preclinical interest, limited direct clinical confirmation.
• Research summary: linalool is repeatedly discussed in relation to stress, mood, and brain-health pharmacology. The 2021 brain-health review found enough preclinical signal to justify continued investigation in neurological and psychiatric contexts, while still emphasizing the lack of robust human trials.
• Additional literature: separate review literature discusses possible antidepressant mechanisms and neuropharmacologic relevance, but this remains a translational rather than definitive clinical story.
• Safety note: as with limonene, oxidized linalool hydroperoxides are recognized allergens in dermatitis literature.

Humulene

• Evidence profile: translationally interesting, but still early.
• Scoping-review findings: a 2024 scoping review analyzed 340 articles and found broad preclinical evidence for anti-inflammatory and other biologic effects, with some rodent work even suggesting cannabimimetic properties via CB1 and adenosine A2a pathways.
• Interpretation caution: those findings are valuable for hypothesis generation, but they do not yet establish consistent human efficacy across pain, inflammation, or mood outcomes.

Terpinolene

• Evidence profile: one of the least clinically characterized terpenes in this file.
• Systematic-review findings: the 2021 terpinolene review screened 2,449 records and included 57 studies, concluding that terpinolene has a range of reported biological effects but that the evidence base is still dominated by in silico, in vitro, and animal studies rather than human trials.
• Interpretation caution: even recent cannabis entourage reviews frame terpene benefits as exploratory, not as established compound-specific clinical effects.

Research limits and interpretation

• The evidence base is highly uneven. CBD and delta-9 THC can support the most detailed human-facing statements; the rest require more caution.
• Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, and terpene-only data are not interchangeable. One common error in cannabis writing is to let evidence from one category stand in for another.
• Minor cannabinoids and terpenes are commercially interesting precisely because they are underexplored, but that also means the claims around them often become inflated.
• Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, and route-dependent pharmacokinetics all materially affect interpretation in real-world products.
• For THCa in particular, chemistry is destiny: storage and heating can change the actual exposure profile by converting acidic cannabinoids into neutral cannabinoids such as THC.

Common overstatements to avoid

• Overstatement: CBN is a clinically proven sleep cannabinoid.
  More accurate: the specific sleep evidence for CBN remains weak and dated, with no strong validated-trial base yet identified.

• Overstatement: myrcene is a proven human sedative that reliably explains couch-lock.
  More accurate: myrcene has plausible preclinical bioactivity, but direct human proof for that common claim is limited.

• Overstatement: terpenes in general have proven entourage effects in patients.
  More accurate: entourage hypotheses are influential and worth studying, but robust clinical proof remains limited and highly compound-specific.

• Overstatement: THCa is always nonpsychoactive.
  More accurate: THCa itself is not THC, but heating and processing can convert THCa into THC, changing the effective exposure.

• Overstatement: delta-8 THC is safe because it is hemp-derived.
  More accurate: delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns.

Practical takeaways for the formulas in this document

• The most evidence-developed actives in these formulas are CBD and delta-9 THC.
• Delta-8 THC is not a trivial or purely mild ingredient; it is a psychoactive cannabinoid with less robust safety and efficacy characterization than delta-9 THC.
• THCa meaningfully changes with processing and should not be interpreted the same way in raw, gently handled, and heated formats.
• CBG, CBN, and CBC are scientifically credible but clinically immature compared with CBD and THC.
• The listed terpenes are likely highly relevant to aroma, flavor, and potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully and only where directly supported.

RSO SUBLINGUAL OIL

Cannabinoid	Amount
CBD	4,500mg
CBG	3,000mg
Delta-8 THC	6,000mg
THCa	1,500mg
Delta-9 THC	90mg
CBN	750mg
CBC	750mg
Total Cannabinoids	16,590mg

• Live Terpenes: 5%
• Format: 30mL bottle
• Active cannabinoids per mL: 553mg

RSO VAPE CARTRIDGE

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%
• Format: 1 Gram cartridge

TERPENE PROFILE (BOTH PRODUCTS)

• Limonene (citrus-bright)
• Myrcene
• Caryophyllene (β-caryophyllene – pepper/spice)
• Pinene (forest-fresh)
• Linalool (floral, lavender)
• Humulene (earthy, woody)
• Terpinolene (piney, fruity, sparkling)

Final thoughts for our friends in Terrell County:

We know this is a lot of information. We wrote it this way because you deserve the complete picture—not the abbreviated version, not the sales pitch, but everything we know about Rick Simpson Oil, about cannabinoid science, about our story, and about how our products might fit into your life here in Terrell County.

If you’re dealing with chronic pain from years of physical labor, if you’re supporting a loved one through cancer treatment, if you’re a veteran carrying trauma that won’t let you sleep, if you’re just curious and want to understand what all the RSO talk is about—we see you. We’ve been there. And we’re here to help you make an informed decision.

Our phone number is (832) 416-2816. Our email is [email protected]. Our website is https://oilwellcbd.com/. We ship nationwide, including to Terrell County, Georgia. Every order includes full documentation, Certificates of Analysis, and discreet packaging.

The choice is yours. We’re just here to make sure you have the best possible version of the information to base it on.

LEGAL DISCLAIMERS AND SAFETY INFORMATION

Age requirement: All RSO products are for ages 21+ only. We do not sell to minors under any circumstances.

THC content compliance: All products contain less than 0.3% delta-9 THC by dry weight, making them Farm Bill compliant and hemp-derived. OilWell RSO Sublingual Oil contains 90mg total delta-9 THC in the entire 30mL bottle (3mg/mL). The product also contains 1,500mg THCa which can be converted to approximately 1,315mg delta-9 THC through decarboxylation at the customer’s discretion.

FDA disclaimer: These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have any health concerns.

Safety warnings: These products may cause drowsiness or impairment. Do not operate vehicles, machinery, or engage in tasks requiring alertness after consuming psychoactive cannabinoids. Use caution when combining with alcohol, sedatives, or other medications. Keep out of reach of children and pets. Store in a cool, dry place away from direct sunlight.

Legal responsibility: Customers are responsible for verifying compliance with local laws before purchasing or using these products. OilWell assumes no legal responsibility for customer’s use, possession, transport, or decarboxylation decisions. Void where prohibited by law.

Drug testing warning: THCa in its raw form is non-psychoactive and may not trigger positive drug tests. However, delta-8 THC, delta-9 THC, and decarboxylated THCa (converted to delta-9 THC) will cause positive results on standard cannabis drug screens. Do not use these products if you are subject to drug testing for employment, legal, or medical reasons without understanding these risks.

Warning for Georgia residents: While these products are federally legal under the 2018 Farm Bill, Georgia state law regarding hemp-derived cannabinoids may evolve. Customers in Terrell County and throughout Georgia accept responsibility for monitoring and complying with current state regulations. Consult legal counsel if you have questions about the legality of specific cannabinoids in Georgia.

Product stability: THCa can slowly decarboxylate to delta-9 THC over time, especially when exposed to heat or light. Store products in a refrigerator to minimize conversion if you wish to maintain non-psychoactive status. For longest shelf life and stability, keep in original packaging in cool conditions.

Drug interactions: Cannabinoids can interact with many prescription medications, including blood thinners, anticonvulsants, antidepressants, and others. If you take prescription medications, consult your prescribing physician or pharmacist before using cannabinoid products.

Medical advice disclaimer: Nothing in this document constitutes medical advice. The condition-specific usage contexts provided are for educational purposes only and must not replace professional medical consultation. Cancer patients, pregnant or nursing individuals, and those with serious medical conditions must involve their healthcare providers in all cannabinoid use decisions.

Emergency guidance: If you experience adverse reactions including severe anxiety, rapid heart rate, chest pain, or difficulty breathing after using these products, seek immediate medical attention. Contact poison control at 1-800-222-1222 if accidental ingestion by children or pets occurs.

Product returns: Due to the nature of these products, OilWell does not accept returns once products have been opened or used. Unopened products may be returned within 30 days of purchase with prior authorization. Contact customer service at (832) 416-2816 or [email protected] for return authorization.

Contact information:

• Phone: (832) 416-2816
• Email: [email protected]
• Website: https://oilwellcbd.com/
• Address: 810 Richmond Ave, Houston, TX 77006
• Hours: Monday-Thursday 10 AM-7 PM, Friday-Saturday 10 AM-10 PM, Sunday 10 AM-4 PM (Central Time)

For Terrell County customers: We ship to all addresses served by USPS in Terrell County, including Dawson, Sasser, Parrott, and rural routes. Delivery typically takes 2-3 business days via Priority Mail. All packages are discreet with no external cannabis branding. We include complete COAs and legal documentation in every shipment to ensure you have full transparency for your records.

References

Simpson R. Phoenix Tears: The Rick Simpson Story. Simpson RamaDur LLC; 2012.

Laurette C, director. Run From The Cure: The Rick Simpson Story . 2005. Distributed via phoenixtears.ca and online platforms.

Simpson R. Instructions and dosing information published on phoenixtears.ca. Multiple dates. Accessed March 2026.

Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012;12(6):436-444. PMID: 22555283.

Guzmán M, Duarte MJ, Blázquez C, et al. A pilot clinical study of delta-9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197-203. PMID: 16804518.

National Cancer Institute. Cannabis and Cannabinoids (PDQ) — Health Professional Version. NIH/NCI. Updated 2024. Available at: https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq

[1] National Center for Complementary and Integrative Health. Cannabis Marijuana and Cannabinoids: What You Need To Know. NIH/NCCIH. Accessed March 2026.

[2] Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Neurol. 2023;359:114238.

[3] Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol CBD in anxiety disorders: A systematic review and meta-analysis. Psychiatry Res. 2024;339:116049.

[4] Cásedas G, Yarza-Sancho M, López V. Cannabidiol CBD: A systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals Basel. 2024;17(11):1438.

[5] Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol in the management of insomnia: A systematic review. Cannabis Cannabinoid Res. 2023;8(2):213-229.

[6] Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. J Intern Med. 2023;293(6):724-752.

[7] Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204-212.

[8] Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, Wang R, Peng J, Yin T, Wang H. Cannabigerol CBG: A comprehensive review of its molecular mechanisms and therapeutic potential. Molecules. 2024;29(22):5471.

[9] Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol delta8 THC: Comparative pharmacology with delta9 THC. Br J Pharmacol. 2022;179(15):3915-3933.

[10] LoParco CR, Rossheim ME, Walters ST, Zhou Z, Olsson S, Sussman SY. Delta-8 tetrahydrocannabinol: A scoping review and commentary. Addiction. 2023;118(6):1011-1028.

[11] Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry and pharmacology of Delta-8-Tetrahydrocannabinol. Molecules. 2024;29(6):1249.

[12] Moreno-Sanz G. Can You Pass the Acid Test? Critical review and novel therapeutic perspectives of delta9-Tetrahydrocannabinolic Acid A. Cannabis Cannabinoid Res. 2016;1(1):124-130.

[13] McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, Chou R. Cannabis-based products for chronic pain: A systematic review. Ann Intern Med. 2022;175(8):1143-1153.

[14] Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360.

[15] Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T. High-concentration delta-9-tetrahydrocannabinol cannabis products and mental health outcomes: A systematic review. Ann Intern Med. 2025;178(10):1429-1440.

[16] Corroon J. Cannabinol and sleep: Separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366-371.

[17] Lavender I, Garden G, Grunstein RR, Yee BJ, Hoyos CM. Using cannabis and CBD to sleep: An updated review. Curr Psychiatry Rep. 2024;26(12):712-727.

[18] Sepulveda DE, Vrana KE, Kellogg JJ, Bisanz JE, Desai D, Graziane NM, Raup-Konsavage WM. The potential of cannabichromene as a therapeutic agent. J Pharmacol Exp Ther. 2024;391(2):206-213.

[19] Zagožen M, Čerenak A, Kreft S. Cannabigerol and cannabichromene in Cannabis sativa L. Acta Pharm. 2021;71(3):355-364.

[20] André R, Gomes AP, Pereira-Leite C, Marques-da-Costa A, Monteiro Rodrigues L, Sassano M, Rijo P, Costa MDC. The entourage effect in cannabis medicinal products: A comprehensive review. Pharmaceuticals Basel. 2024;17(11):1543.

[21] Anandakumar P, Kamaraj S, Vanitha MK. D-limonene: A multifunctional compound with potent therapeutic effects. J Food Biochem. 2021;45(1):e13566.

[22] Ogueta IA, Brared Christensson J, Giménez-Arnau E, Brans R, Wilkinson M, Stingeni L, Foti C, Aerts O, Svedman C, Gonçalo M, Giménez-Arnau A. Limonene and linalool hydroperoxides review: Pros and cons for routine patch testing. Contact Dermatitis. 2022;87(1):1-12.

[23] Surendran S, Qassadi F, Surendran G, Lilley D, Heinrich M. Myrcene: What are the potential health benefits of this flavouring and aroma agent? Front Nutr. 2021;8:699666.

[24] Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Al Kaabi J, Ojha S. A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of beta-caryophyllene, a dietary cannabinoid. Biomed Pharmacother. 2021;140:111639.

[25] Weston-Green K, Clunas H, Jimenez Naranjo C. A review of the potential use of pinene and linalool as terpene-based medicines for brain health: Discovering novel therapeutics in the flavours and fragrances of cannabis. Front Psychiatry. 2021;12:583211.

[26] Dos Santos ÉRQ, Maia JGS, Fontes-Júnior EA, do Socorro Ferraz Maia C. Linalool as a therapeutic and medicinal tool in depression treatment: A review. Curr Neuropharmacol. 2022;20(6):1073-1092.

[27] Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. The clinical translation of alpha-humulene: A scoping review. Planta Med. 2024;90(9):664-674.

[28] Menezes IO, Scherf JR, Martins AOBPB, Ramos AGB, Quintans JSS, Coutinho HDM, Ribeiro-Filho J, de Menezes IRA. Biological properties of terpinolene evidenced by in silico, in vitro and in vivo studies: A systematic review. Phytomedicine. 2021;93:153768.

[29] Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364.

For our neighbors in Terrell County, Georgia:

We know you’re far from Houston. We know you don’t have a cannabis shop on Main Street in Dawson. We know the healthcare options are limited and the legal landscape is confusing. That’s exactly why we built this company the way we did—to serve people in places like Terrell County who deserve the same access and information as people in big cities.

Every word in this document is here because we believe you deserve the truth. The full truth. Not the abbreviated version, not the sales pitch, but everything we know about Rick Simpson Oil, about cannabinoid science, about our story, and about how this might help you.

If you have questions, call us at (832) 416-2816. If you want to order, visit https://oilwellcbd.com/. If you want to make your own using our open-source formulas, that’s okay too. The knowledge is yours.

This is what medicine should look like in 2024—transparent, evidence-informed, patient-controlled, and accessible whether you live in Houston or Terrell County, Georgia.

Take care of yourselves, and each other.